SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?


To: Caroline who wrote (3087)5/31/1998 12:20:00 PM
From: Solid  Read Replies (1) | Respond to of 9523
 
FYI-



'Coattail marketing' is under fire by maker of Viagra
San Antonio Express-News

TRENTON, N.J. - Entrepreneurs peddling
audiotapes, herbal remedies, even sunglasses,
are trying to make the most of the flimsiest links
to Viagra to make a buck off the impotence pill
craze.

Las Vegas-based BluBlocker Corp. says its "BluBlocker Viagra" shades
help mask the blue tinge Viagra adds to some users' vision.

"This is crass commercialism," conceded BluBlocker chairman Joseph
Sugarman. "I just couldn't resist the opportunity to tie in with that product."

While some companies might be reaching a little far to take advantage of
Viagra, others say they're merely acknowledging a link consumers have
already made.

For [ Bradley Pharmaceuticals ] , newly sexually active men have created a
new batch of customers for its vaginal lubricant. Bradley's pitch: "What
Viagra does for him, Lubrin does for her."

Bradley executives say they noticed a jump in sales of their Lubrin vaginal
suppositories. They credited Viagra, or more precisely, an increase in the
number of aging women bothered by vaginal dryness who are dealing with
reinvigorated Viagra users.

Marketing vice president Gene Goldberg hopes to ride the trend by
increasing Lubrin production dramatically and introducing a new liquid
lubricant months ahead of schedule - linking the product to the impotence
pill in ads.

Some companies are clearly flouting trademark laws, and Pfizer is fighting
back.

"We expect that there will be copycats or attempts at coattail marketing,"
said Andy McCormick, spokesman for Viagra's maker, [ Pfizer Inc. ] of
New York. "When they step over the line in terms of the law, we will step
in."

That's already happened in three cases, Nels Lippert, an attorney for Pfizer,
said Tuesday.

Blublocker chairman Sugarman says he'll probably give away the 200 pairs
already made, after Pfizer attorneys threatened a lawsuit "that kind of
dampened our enthusiasm."

Two other companies have run afoul of Pfizer attorneys since Viagra was
approved for sale March 27.

Both sell herbal supplements over the Internet and were promoting sexual
potency products with extremely similar names: Vaegra and Viagro.

"They've capitulated," after Pfizer filed trademark infringement suits, Lippert
said.

Courts in Georgia and New York promptly issued temporary restraining
orders barring outfits called the Institute of Sexual Research and Consumer
Protection Services from selling the products.

Other Viagra-related ventures aren't blocked by trademark laws, though.

At least three books on Viagra and impotence treatment are on the market,
including one by New York internist Dr. Steven Lamm, "The Virility
Solution."

Some herbal supplement makers are promoting products with names such
as NuMan and Stamina as natural alternatives to the Pfizer medication.

And a subliminal audiotape maker, HypnoVision Inc., has gotten nearly
1,000 orders for its mood-enhancing tape, newly reworked to include
messages like, "My body works perfectly during sex because my Viagra is
working."

Other businesses naturally stand to benefit from the sex surge.

Durex Consumer Products, the world's top condom maker, says sales
began climbing slightly about five weeks ago as pharmacists started stocking
Viagra.

The increase is more dramatic at Condom Express, which distributes
condoms and "intimate lubricants" over the Internet. Sales of both more than
doubled starting in March, when hype about Viagra's anticipated arrival
began.

"I don't know if it's from Viagra," company president Bruce Gasparre said.
"It's quite possible."

Pharmaceutical industry analyst Hemant Shah in Warren, N.J., expects an
increase in oral contraceptive sales as younger men, and even women,
experiment with Viagra, which is only approved for use by impotent men.

"That's a second coattail you may see," Shah said.

Some companies are clear losers, though.

Prior to April 6, when Viagra began hitting store shelves, about 22,000 U.S.
prescriptions were filled each week for four impotence drugs that are either
injected into the penis or inserted directly into the urinary tract.

By the first week of May, only 10,179 were filled for those impotence
treatments, compared to 303,424 Viagra prescriptions, 92 percent of them
to new customers, according to IMS Health, an information consulting firm
in Plymouth Meeting, Pa.

(Copyright 1998)

_____via IntellX_____

Publication Date: May 31, 1998



To: Caroline who wrote (3087)5/31/1998 12:26:00 PM
From: Solid  Read Replies (1) | Respond to of 9523
 
Bigk-

How about this one...Zanogen -and does June mean it would be available when? I dislike ambiguous wording as with the 2nd to last paragraph here. I think it means by end of June they will be ASKING for FDA to look into approval.



RESEARCH - NEW, FASTER IMPOTENCY DRUGS IN
WORKS
Dayton Daily News

* Analysts say those looking to cut into Viagra's
market share may fare even better.

NEW YORK - While the frenzy for Viagra
continues, drug companies are developing
competitors that could work faster or eliminate some of the side effects of
the impotence treatment.

The market is vast and its growth has been phenomenal. More than 1 million
men have filled prescriptions for Viagra, made by [ Pfizer Inc. ] , since it was
approved by federal regulators March 27.

Analysts say Viagra could reach $1 billion in sales this year. The next
impotence drug isn't likely to emerge until next year, and by then, drug
makers looking to cut into Viagra's market share may fare better if their
treatments work faster or last longer.

"The second or third drug on the market, as long as it's safe and effective,
should also do well," said Hemant K. Shah, an independent industry analyst
in Warren, N.J. "But Viagra will be quite entrenched."

[ Zonagen Inc. ] , of The Woodlands, Texas, may be next in line. It recently
completed clinical tests on Vasomax, which dissolves more rapidly in the
stomach than Viagra.

Jean Anne Mire, the company's vice president of investor relations, said a
patient can develop an erection within 15 to 30 minutes of taking Vasomax.

Zonagen expects to formally ask the Food and Drug Administration to
approve the drug by the end of June.

Pfizer is working on a Viagra wafer that could dissolve in the mouth in
seconds, which would let patients take the drug only minutes before sex.

(Copyright 1998)

_____via IntellX